1. Introduction {#sec1-jcm-08-01731}
===============

Sepsis is considered the most frequent cause of acute kidney injury (AKI) in critically ill patients in the intensive care unit (ICU) \[[@B1-jcm-08-01731]\]. It is a heterogeneous syndrome caused by an unbalanced host response to an infection, often resulting in variable clinical signs and symptoms. Until the early 1990s, sepsis was not formally defined, and numerous different criteria were used in research and clinical practice. In 2016, the 'Sepsis-3' consensus definition was published. Accordingly, sepsis constitutes life-threatening organ dysfunction that is caused by a dysregulated host response to infection and defined by an acute change in total Sequential Organ Failure Assessment (SOFA) score by ≥2 points (delta SOFA). In addition, the concept of the quick SOFA (qSOFA) was introduced as a possible tool to identify patients with sepsis outside the ICU \[[@B2-jcm-08-01731]\]. The qSOFA describes the presence of any two of the following three factors: Respiratory rate ≥ 22/min, altered mentation or systolic blood pressure ≤ 100 mmHg. Septic shock is recognized as a subset of sepsis with profound circulatory, cellular, and metabolic abnormalities as evidenced by a serum lactate concentration \>2 mmol/L and vasopressor requirement to maintain a mean arterial pressure (MAP) of at least 65 mmHg in the absence of hypovolemia. Of note, the terms systemic inflammatory response syndrome (SIRS) and severe sepsis were removed.

An analysis of data from a large cohort of patients admitted to 409 hospitals in the USA in 2004--2009 revealed that more than 40% of patients with sepsis, as defined by the Sepsis-3 criteria, also had AKI \[[@B3-jcm-08-01731]\]. In patients with AKI, mortality and long-term outcomes are worst in those treated with renal replacement (RRT), also known as 'AKI with dialysis' (AKI-D) \[[@B2-jcm-08-01731],[@B4-jcm-08-01731]\]. To date, the prevalence and outcomes of sepsis defined by the Sepsis-3 criteria among AKI-D patients has not been well reported. It is unclear whether the two criteria of the Sepsis-3 definition are equally predictive when used in association with AKI-D patients.

The aims of our project were: (i) To describe the incidence, outcomes, and characteristics of sepsis, as defined by the screening Sepsis-3 criteria, among AKI-D patients; and (ii) to show the outcomes of AKI-D patients without or with sepsis.

2. Methods {#sec2-jcm-08-01731}
==========

2.1. Study Population {#sec2dot1-jcm-08-01731}
---------------------

We analyzed data of the Taiwan Consortium for Acute Kidney Injury and Renal Diseases (CAKs) study. The CAKS study was approved by the institutional review boards of the participating institutions. The need for informed consent was waived because all personal data was fully de-identified and only data that were routinely collected for clinical purposes were analyzed (approval number NRPB2014050014). The CAKs study has been extensively described previously \[[@B5-jcm-08-01731],[@B6-jcm-08-01731]\]. In brief, it is a prospective observational study of ICU patients with AKI-D admitted to one of 30 hospitals in Taiwan. The hospitals are distributed widely through the various geographical regions of Taiwan (north, middle, south, and east) and there is a 1:1 ratio of tertiary medical centers to regional hospitals in each region. We analyzed patients who had been enrolled in four distinct months (October 2014, January 2015, April 2015 and July 2015) and were followed-up for at least three months after hospital discharge. Patients receiving chronic dialysis before the index hospitalization were excluded.

2.2. Dialysis Initiation {#sec2dot2-jcm-08-01731}
------------------------

The pre-determined indications for RRT protocol or algorithm or simply clinician judgement were: (1) Presence of azotemia (blood urea nitrogen (BUN) \> 80 mg/dL and serum creatinine (sCr) \> 2 mg/dL) and uremic symptoms (encephalopathy, pericarditis or pleurisy); (2) oliguria (urine output \< 400 mL/24 h) or anuria refractory to fluid challenges and diuretics; (3) fluid overload refractory to diuretics with a central venous pressure (CVP) \> 12 mmHg or pulmonary edema with a PaO2/FiO2 \< 300 mmHg; (4) hyperkalemia (serum potassium \> 5.5 mmol/L) refractory to medical treatment, and/or (5) metabolic acidosis (arterial pH \< 7.2) \[[@B7-jcm-08-01731],[@B8-jcm-08-01731],[@B9-jcm-08-01731]\].

2.3. Infection and Sepsis {#sec2dot3-jcm-08-01731}
-------------------------

The medical records of all patients were independently reviewed by two investigators to identify AKI-D patients who met the Sepsis-3 criteria at initiation of RRT. In case of any discordance, a third investigator (VCW) acted as an adjudicator.

To be classified as having sepsis, patients with a suspected or confirmed infection had to have at least two qSOFA criteria \[[@B10-jcm-08-01731]\] or an acute increase in total SOFA score by ≥2 within the 24 h period before acute RRT was started (distribution as [Figure S1](#app1-jcm-08-01731){ref-type="app"}). Infection was defined as body fluids with positive culture or antibiotics started as a criterion of suspected infection. In patients with a nosocomial infection in whom a pre-admission SOFA score was not available, the first SOFA value at hospital admission qualified as baseline score (1). Patients with hepatic dysfunction who received acute RRT within 24 h of ICU admission, were assigned a baseline SOFA score of four, and in case of chronic respiratory impairment, a baseline score of two was assigned \[[@B11-jcm-08-01731]\]. In all other cases, the baseline SOFA score was considered to be zero \[[@B2-jcm-08-01731]\]. Consistent with previous studies, missing values were considered to be normal \[[@B10-jcm-08-01731]\].

2.4. Outcomes {#sec2dot4-jcm-08-01731}
-------------

The primary study outcome was 90-day mortality after hospital discharge. Secondary outcomes were inability to wean from acute RRT and/or a composite outcome of mortality or RRT dependence at 90 days after hospital discharge \[[@B12-jcm-08-01731]\].

2.5. Clinical Data Collection {#sec2dot5-jcm-08-01731}
-----------------------------

In patients with AKI-D at initiation of RRT, we extracted the following data: Baseline characteristics and demographics, severity of illness scores including SOFA score, acute physiology and chronic health evaluation II (APACHE II) score and multiple organ dysfunction syndrome (MODS) score, comorbidities and the presumed etiology of AKI. AKI was defined by the serum creatinine criteria of the Kidney Disease Improving Global Outcome classification \[[@B13-jcm-08-01731]\]. We also calculated the AKI risk prediction score as proposed by Demirjian et al. \[[@B14-jcm-08-01731]\] ([Table S1](#app1-jcm-08-01731){ref-type="app"}). The worst physiological and biochemical values during the initial 24-h period before RRT were recorded, together with the severity of illness scores and vasopressor administration at initiation of RRT \[[@B15-jcm-08-01731]\].

The pre-determined indications for RRT were mentioned above and as in supplemental methods.

2.6. Statistical Analyses {#sec2dot6-jcm-08-01731}
-------------------------

Continuous data were expressed as mean ± standard deviation (SD) and group comparisons were conducted using χ 2 tests for equal proportions, t tests for normally distributed data, and Wilcoxon rank sum tests otherwise.

We performed multivariable analyses of all factors that were significant in univariate analyses, including age, sex, baseline comorbidities, indication for RRT, etiology of AKI, renal parameters and SOFA score at initiation of RRT and modality of RRT. The significance levels for entry (SLE) and for stay (SLS) were set at a conservative level of 0.15. The best candidate final logistic regression model was identified manually by dropping the covariates with a *p* value \> 0.05 one at a time until all regression coefficients were significantly different from zero.

Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) analysis were used to examine the role of the Sepsis-3 criteria to stratify individuals into higher or lower risk categories (reclassification) \[[@B16-jcm-08-01731],[@B17-jcm-08-01731]\]. Focusing on 90-day mortality, an increase in NRI was calculated in a model containing the Sepsis-3 criteria in combination with the AKI risk prediction or SOFA score. The results were compared with the individual criteria of the Sepsis-3 definition. We distinguished between three risk categories (0%--40%, 40%--80%, and \>80%) and reclassified the patients who died from all-causes or were still dialysis dependent at 90 days after hospital discharge (according to decision curve analysis, [Figure S2](#app1-jcm-08-01731){ref-type="app"}).

All analyses were performed with R software, version 3.2.2 (Free Software Foundation, Inc., Boston, MA, USA), MedCalc Statistical Software, version 15.11.3 (MedCalc Software bvba, Ostend, Belgium; <https://www.medcalc.org;> 2015) and Stata version 12 (StataCorp LP, College Station, TX, USA) for competing-risk analysis. A *p*-value \< 0.05 was considered significant.

3. Results {#sec3-jcm-08-01731}
==========

3.1. Patient Cohort {#sec3dot1-jcm-08-01731}
-------------------

We enrolled a total of 1078 critically ill patients with AKI-D (median age 70 years; 673 (62.4%) male). At initiation of RRT, their median SOFA score was 12, APACHE II score 24 and MODS score was 11. A total of 577 (53.5%) patients had sepsis, of whom 206 (19.1%) met the criteria for septic shock ([Figure 1](#jcm-08-01731-f001){ref-type="fig"}). [Supplementary Figure S1](#app1-jcm-08-01731){ref-type="app"} shows the distribution of the qSOFA and SOFA scores. The main source of infection was the respiratory tract (53.6%), followed by the genitourinary tract (31.4%). The missing data were mainly come from bilirubin (*n* = 4, 3.7%) and coagulation INR (5, 4.6%).

Based on judgment by the clinicians treating the patients, the main etiologies of AKI were sepsis (71.4%), shock (57.1%) and rhabdomyolysis (14.4%). The most frequent indication for acute RRT was oliguria (64.4%), followed by fluid overload (56.0%), azotemia (54.4%) and metabolic acidosis (49.6%).

3.2. Impact of Sepsis {#sec3dot2-jcm-08-01731}
---------------------

Patients with AKI-D who had sepsis (53.5%) or septic shock (19.1%) at initiation of RRT were significantly older, had better baseline renal function and a higher serum lactate result on admission to ICU compared to AKI-D patients without sepsis ([Table 1](#jcm-08-01731-t001){ref-type="table"}).

3.3. Comparison between 90-Day Survivors and Non-Survivors {#sec3dot3-jcm-08-01731}
----------------------------------------------------------

Mortality and composite outcome (mortality or RRT dependence) at 90 days were 62.3%, and 76.4% in the 1078 AKI-D patients, respectively ([Table 2](#jcm-08-01731-t002){ref-type="table"}). Sepsis and septic shock were more common among non-survivors compared to survivors (63.2% and 25.6% versus 37.4% and 8.4%, respectively). Other significant differences between 90-day survivors and non-survivors were older age, a higher comorbidity score, lower baseline serum creatinine and a higher prevalence of liver cirrhosis and cancer in non-survivors.

3.4. Sepsis-3 Criteria versus 90-Day Outcomes {#sec3dot4-jcm-08-01731}
---------------------------------------------

Multivariable analysis showed that AKI-D patients with sepsis or septic shock at initiation of RRT had a significantly higher risk of mortality at 90 days compared to AKI-D patients without sepsis ([Table 3](#jcm-08-01731-t003){ref-type="table"} and [Figure 2](#jcm-08-01731-f002){ref-type="fig"}a). There was a positive correlation between the Sepsis-3 criteria and APACHE II score (*r* = 0.385, *p* \< 0.001), SOFA score (*r* = 0.391, *p* \< 0.001) and AKI risk prediction score (*r* = 0.359, *p* \< 0.001). AKI-D patients with septic shock had a greater incremental increase in 90-day mortality across all deciles of APACHE II at initiation of RRT compared to AKI-D patients with qSOFA ≥ 2 ([Figure S4, Table S2](#app1-jcm-08-01731){ref-type="app"}).

3.5. Sepsis per Sepsis-3 Criteria versus the Risk of Dialysis Dependence {#sec3dot5-jcm-08-01731}
------------------------------------------------------------------------

Multivariable analysis showed that after controlling for mortality, AKI-D patients with septic shock who survived had a significantly lower likelihood of weaning from dialysis, when compared to AKI-D patients without sepsis (hazard ratio (HR), 0.65, *p* = 0.026) ([Table 3](#jcm-08-01731-t003){ref-type="table"}). There was no significant difference in likelihood of weaning from dialysis at 90 days between AKI-D patients without sepsis and AKI-D patients with sepsis but without septic shock (HR 0.96, *p* = 0.760) ([Table 3](#jcm-08-01731-t003){ref-type="table"}, [Figure 2](#jcm-08-01731-f002){ref-type="fig"}b).

3.6. Evaluation of Sepsis-3 Criteria in Combination with AKI Risk Prediction Score and SOFA Score versus the 90 Days Mortality {#sec3dot6-jcm-08-01731}
------------------------------------------------------------------------------------------------------------------------------

Combining the Sepsis-3 criteria with the AKI risk prediction score at initiation of RRT led to a significant increase in risk stratification (total NRI = 0.07; 95% CI, 0.02--0.11; *p* \< 0.01). The majority of this effect came from those without death (NRI event = 0.04; 95% CI, 0.01--0.07; *p* = 0.039). Likewise, the total IDI was significant (0.02, 95% CI, 0.01--0.02; *p* \< 0.001).

In case of sequential diagnosis of sepsis according to the Sepsis-3 criteria, we added Sepsis-3 to the qSOFA criteria in estimating the risk of 90-day mortality after initiation of dialysis. This led to a significant increase in risk stratification (total NRI = 0.11; 95% CI, 0.04--0.19; *p* = 0.004). The majority of this effect came from those without death (NRI event = 0.07; *p* = 0.03), whereas the NRI with death was 0.05 (NRI non-event = 0.04, *p* = 0.049) ([Figure S3](#app1-jcm-08-01731){ref-type="app"}). Similarly, the total integrated discrimination improvement (IDI) was significant at 0.06 (95% CI, 0.03 to 0.05; *p* \< 0.001).

4. Discussion {#sec4-jcm-08-01731}
=============

To our best knowledge, this is the first study that applied the most recent Sepsis-3 screening criteria to the patients with AKI-D. The key findings of this large multi-center prospective study are that sepsis affects 53.5% of patients with AKI-D, and that at time of RRT 19.1% of patients had septic shock. The chances of renal recovery at 90 days were significantly lower in AKI-D patients with septic shock compared to those without sepsis. Presence of sepsis per Sepsis-3 criteria in AKI-D patients is associated with higher mortality rate and composite outcome at 90 days. Combining the Sepsis-3 criteria with the AKI risk score or SOFA criteria led to a further improvement in risk identification.

A 53.5% prevalence of sepsis among AKI-D patients is slightly higher than previously reported \[[@B18-jcm-08-01731]\]. This may be a reflection of our specific patient cohort of critically ill ICU patients or a result of using the Sepsis-3 criteria. Similarly, in-hospital mortality rate of this cohort was high, including its non-septic controls (44.1%), which again may be explained by the characteristics of our patient population (older age, high comorbidity and acute severity of illness scores) and the criteria used to identify patients.

4.1. Association of Mortality and Non-Recovery from Dialysis {#sec4dot1-jcm-08-01731}
------------------------------------------------------------

Patients with AKI requiring RRT constitute a high-risk group. An accurate prognostic assessment is crucial for clinical management and planning of future care. The Sepsis-3 criteria identified AKI-D patients with a suspected or confirmed infection who were at increased risk of mortality, and a combo endpoint of mortality or dialysis dependence at 90 days. Our data also showed that the criteria to define septic shock (i.e., a raised serum lactate level and the need for inotropic support) indeed identified the subgroup of patients with the highest mortality (\>80%).

The Sepsis-3 criteria correlated with SOFA and APACHE II scores at initiation of dialysis which underpins the potential use of Sepsis-3 in a critical care setting. It can be hypothesized that a higher Sepsis-3 score also reflects a higher degree of systemic inflammation.

Data on the risk of long-term dialysis dependence in AKI-D patients with sepsis are conflicting \[[@B18-jcm-08-01731],[@B19-jcm-08-01731]\], similar to a French multicentric study \[[@B19-jcm-08-01731]\]. We found a statistically significant trend towards reduced likelihood of recovery from dialysis in AKI-D patients with septic shock compared to those without sepsis. In contrast, Bagshaw and colleagues analyzed data from 2000/2001 and reported improved renal recovery in patients with septic AKI compared to patients without sepsis \[[@B18-jcm-08-01731]\]. It is important to note that there were differences in patient characteristics, criteria to define sepsis and clinical care. Moreover, our analysis has extra strength by including mortality as a competing outcome for analysis of dialysis dependence.

4.2. Sepsis-3 Criteria and Outcome {#sec4dot2-jcm-08-01731}
----------------------------------

It is important to emphasize that most AKI patients already had a SOFA score of two or more at the time when RRT was initiated simply as a result of AKI and oliguria. It is possible that different delta SOFA cut-off points are necessary for this patient cohort to differentiate sepsis from non-sepsis ([Figure S6](#app1-jcm-08-01731){ref-type="app"}). As such, our results provide confirmation that AKI-D patients with sepsis, as defined by Sepsis-3 criteria, had higher mortality and less withdraw from dialysis in AKI-D patients with septic shock.

Combining the Sepsis-3 criteria with a clinical AKI risk prediction score resulted in greater IDI and NRI, and improved the ability associating subsequent death. Given the lack of appropriate risk stratification tools for septic AKI patients requiring RRT, the new Sepsis-3 criteria may associate patients outcome ([Figures S3 and S5](#app1-jcm-08-01731){ref-type="app"}).

4.3. Strengths and Limitations {#sec4dot3-jcm-08-01731}
------------------------------

This is the first study that applied the new consensus criteria for sepsis to AKI-D patients, a cohort of patients that is known to have a high risk of sepsis and also a high risk of poor outcomes. Using a large multi-center national database with prospectively collected representative data from 30 ICUs, we showed for the first time that the Sepsis-3 criteria identified a group of patients that were at higher risk of dying or remaining dialysis dependent after discharge. With complete follow-up for 90 days after discharge from hospital, we focused on patient-centered outcomes (mortality and long-term dialysis dependence) and provide important data for a group of patients that is commonly seen in ICUs worldwide. Further in-depth studies are mandatory before we can make any positive comment on this issue.

The limitations of our study are related to any observational cohort study and include the possibility of both unmeasured and residual confounding factors. We could not identify how many patients received early goal-directed therapy in our cohort, however the nationwide education program instituted in Taiwan is able to positively change critical-care physician behavior in sepsis care following the Surviving Sepsis Campaign guidelines. We also acknowledge that we recorded the worst value of SOFA criteria within 24 h before initiation of dialysis. Although this approach is consistent with clinical practice, the daily SOFA score or qSOFA value may not reflect the value immediately before initiation of RRT.

5. Conclusions {#sec5-jcm-08-01731}
==============

More than half of the critically ill AKI patients treated with dialysis had sepsis, as defined by the Sepsis-3 criteria, at dialysis initiation, and one-fifth of AKI-D patients had septic shock screened by Sepsis-3 criteria. Having sepsis and septic shock were independently associated with 90-day mortality among these ICU AKI-D patients. Among survivors, AKI-D patients with septic shock had a significantly reduced chance of recovering sufficient renal function to wean-off dialysis, when compared to those without sepsis. These findings provide support for the use of Sepsis-3 criteria in the AKI-D patients.
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###### 

Clinical characteristics of patients with and without sepsis.

                                              Non-Sepsis          Sepsis              Septic Shock        *p* Value
  ------------------------------------------- ------------------- ------------------- ------------------- -----------
  Patient characteristics                                                                                 
  Age, median (range)                         71.8 (60.6--80.3)   69.3 (57.6--79.7)   65.8 (54.3--76.3)   0.011
  Male gender, *n* (%)                        299 (59.68%)        228 (61.46%)        146 (70.87%)        0.018
  BMI, median (range)                         23.9 (21.4--27.2)   24 (21--27.2)       23.9 (21--26.9)     0.579
  Charlson comorbidity index                  7 (5--9)            7 (5--9)            6 (5--8)            0.020
  Baseline sCr (mg/dL), median (range)        1.7 (1--3.3)        1.4 (0.9--2.4)      1 (0.8--1.7)        \<0.001
  eGFR (ml/min/1.73 m^2^), median (range)     32.5 (15.5--63.3)   44 (21.9--73.8)     63.9 (35.2--88)     \<0.001
  Comorbidities, *n* (%)                                                                                  
  Diabetes mellitus, *n* (%)                  276 (55.09%)        189 (50.94%)        97 (47.09%)         0.131
  Liver cirrhosis, *n* (%)                    56 (11.18%)         58 (15.63%)         40 (19.42%)         0.011
  COPD, *n* (%)                               43 (8.58%)          29 (7.82%)          12 (5.83%)          0.462
  CAD, *n* (%)                                156 (31.14%)        102 (27.49%)        52 (25.24%)         0.233
  CVA, *n* (%)                                78 (15.57%)         59 (15.90%)         22 (10.68%)         0.185
  Hemiplegia, *n* (%)                         22 (4.39%)          20 (5.39%)          6 (2.91%)           0.383
  GI bleeding, *n* (%)                        129 (25.75%)        109 (29.38%)        58 (28.16%)         0.479
  Dementia, *n* (%)                           11 (2.20%)          12 (3.23%)          9 (4.37%)           0.282
  Cancer, *n* (%)                             86 (17.17%)         79 (21.29%)         63 (30.58%)         \<0.001
  Congestive heart failure, *n* (%)           194 (48.7%)         159 (58.49%)        68 (44.66%)         \<0.001
  Laboratory data at ICU admission                                                                        
  BUN (mg/dL), median (range)                 61 (34.5--95.9)     57.7 (27--92)       42 (23.2--68.8)     \<0.001
  sCr (mg/dL), median (range)                 3.7 (2--6.4)        2.7 (1.4--5)        2.3 (1.3--3.8)      \<0.001
  Lactate (mmol/L), median (range)            2.5 (1.4--5.6)      2.4 (1.3--4.8)      6.3 (2.9--10)       \<0.001
  Etiology of AKI (except sepsis), *n* (%)                                                                
  Shock                                       225 (44.91%)        203 (54.72%)        188 (91.26%)        \<0.001
  Cardiorenal syndrome                        206 (41.12%)        134 (36.12%)        53 (25.73%)         \<0.001
  Drug nephrotoxicity                         26 (5.19%)          18 (4.85%)          10 (4.85%)          0.969
  Rhabdomyolysis                              34 (6.79%)          24 (6.47%)          23 (11.17%)         0.086
  Intravascular hemolysis                     16 (3.19%)          10 (2.70%)          8 (3.88%)           0.735
  Hepatorenal                                 26 (5.19%)          22 (5.93%)          21 (10.19%)         0.043
  ATIN                                        4 (0.80%)           5 (1.35%)           0 (0%)              0.276
  Contrast                                    38 (7.58%)          24 (6.47%)          13 (6.31%)          0.750
  Obstructive                                 8 (1.60%)           3 (0.81%)           1 (0.49%)           0.472
  Others                                      117 (23.35%)        56 (15.09%)         24 (11.65%)         \<0.001
  At initiation of RRT                                                                                    
  Urine output (mL/24 h), median (range)      450 (150--1095)     250 (70--620)       130 (50--418)       \<0.001
  AKI risk prediction score, median (range)   22 (17--28)         27 (21--33)         33.5 (26--40)       \<0.001
  Lactate (mmol/L), median (range)            2.2 (1.3--5.2)      1.6 (1--3.1)        6.6 (3.4--10.7)     \<0.001
  SOFA score, median (range)                  10 (7--13)          12 (10--15)         15 (13--17)         \<0.001
  qSOFA, median (range)                       1 (1--1)            2 (2-3)             2 (2--3)            \<0.001
  APACHE II score, median (range)             20 (16--25)         25 (21--30)         27 (22.8--33)       \<0.001
  MODS score, median (range)                  9 (7--11)           12 (10--14)         12 (10--15)         \<0.001
  Site of infection, *n* (%)                                                                              
  Respiratory                                 227 (45.31%)        237 (63.88%)        114 (55.34%)        \<0.001
  GU                                          156 (31.14%)        129 (34.77%)        53 (25.73%)         0.080
  Bacteremia                                  96 (19.16%)         84 (22.64%)         57 (27.67%)         0.043
  Abdomen                                     41 (8.18%)          40 (10.78%)         33 (16.02%)         0.009
  Others                                      56 (11.18%)         38 (10.24%)         21 (10.19%)         0.880
  Indication for dialysis, *n* (%)                                                                        
  Azotemia                                    291 (58.08%)        225 (60.65%)        70 (33.98%)         \<0.001
  Fluid overload                              245 (48.90%)        225 (60.65%)        134 (65.05%)        \<0.001
  Electrolyte imbalance                       190 (37.92%)        148 (39.89%)        79 (38.35%)         0.835
  Metabolic acidosis                          210 (41.92%)        192 (51.75%)        133 (64.56%)        \<0.001
  Oliguria                                    275 (54.89%)        255 (68.73%)        164 (79.61%)        \<0.001
  Uremic encephalopathy                       46 (9.18%)          26 (7.01%)          6 (2.91%)           0.014
  Dialysis modality, *n* (%)                                                                              \<0.001
  CVVH                                        128 (25.55%)        110 (29.65%)        133 (64.56%)        
  IHD                                         334 (66.67%)        252 (67.92%)        58 (28.16%)         
  SLEDD                                       39 (7.78%)          9 (2.43%)           15 (7.28%)          
  Outcomes of interest                                                                                    
  Dialysis days in hospital, median (range)   12 (4--26)          10 (4--27)          6 (3--15)           0.012
  Hospital mortality, *n* (%)                 221 (44.11%)        228 (61.46%)        167 (81.07%)        \<0.001
  90-day ICU free days                        63 (0--85)          1 (0--78)           0 (0--0)            \<0.001
  90-day hospital free days                   30 (0--70)          0 (0--53)           0 (0--0)            \<0.001
  90-day mortality, *n* (%)                   246 (49.10%)        253 (68.19%)        172 (83.49%)        \<0.001
  90-day composite outcome, *n* (%)           352 (70.26%)        296 (79.78%)        175 (84.95%)        \<0.001

Paired comparison between the groups. Abbreviations: AKI, acute kidney injury; APACHE; acute physiology and chronic health evaluation; ATIN, acute tubule-interstitial nephritis; BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CVA, cerebrovascular accident; CVVH, continuous veno-venous hemofiltration; CPR, cardio-pulmonary resuscitation; eGFR, estimated glomerular filtration rate; GSC, Glasgow Coma Scale; GI, gastrointestinal; GU, genitourinary; IABP, intra-aortic balloon pump; ICU, intensive care unit; IHD, intermittent hemodialysis; IQR, interquartile range; MODS, multiple organ dysfunction; RRT, renal replacement therapy; sCr, serum creatinine; SLEDD, sustained low efficiency daily dialysis; SOFA, Sequential Organ Failure Assessment.
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###### 

Clinical characteristics of survivors and non-survivors.

                                               All                  90 Day Survivors    90 Day Mortality   *p* Value   No Dialysis Dependence or Mortality at 90 Days   Dialysis Dependence or Mortality at 90 Days   *p* Value
  -------------------------------------------- -------------------- ------------------- ------------------ ----------- ------------------------------------------------ --------------------------------------------- -----------
  Baseline characteristics                                                                                                                                                                                            
  Age, median (range)                          70 (57.8--79.5)      69 (56.7--77.4)     71 (58.9--81)      0.014       67.7 (53.9--76.8)                                70.9 (59.8--80.4)                             \<0.001
  Male gender, *n* (%)                         673 (62.43%)         247 (60.84%)        426 (63.39%)       0.401       158 (62.20%)                                     515 (62.50%)                                  0.932
  BMI, median (range)                          23.95 (21.2--27.1)   24.2 (21.5--27.6)   23.7 (21--26.8)    0.870       24.6 (22--27.9)                                  23.7 (21--26.8)                               0.598
  Charlson comorbidity index, median (range)   7 (5--9)             7 (5--8.3)          7 (5--9)           0.001       6 (4--8)                                         7 (5--9)                                      \<0.001
  Baseline sCr (mg/dL), median (range)         1.4 (0.9--2.7)       1.8 (1--3.6)        1.3 (0.9--2.3)     \<0.001     1.2 (0.9--2.1)                                   1.5 (0.9--2.8)                                \<0.001
  eGFR (mL/min/1.73 m^2^), median (range)      41.79 (20.4--73.6)   31.9 (14.6-64.3)    48.2 (24.4-77.1)   \<0.001     49.9 (25.3-78)                                   40.5 (18.2-71.7)                              0.040
  Comorbidities                                                                                                                                                                                                       
  Diabetes mellitus, *n* (%)                   562 (52.13%)         228 (56.16%)        334 (49.70%)       0.040       139 (54.72%)                                     423 (51.33%)                                  0.344
  Liver cirrhosis, *n* (%)                     154 (14.29%)         26 (6.40%)          128 (19.05%)       \<0.001     19 (7.48%)                                       135 (16.38%)                                  \<0.001
  COPD, *n* (%)                                84 (7.79%)           31 (7.64%)          53 (7.89%)         0.881       19 (7.48%)                                       65 (7.89%)                                    0.832
  CAD, *n* (%)                                 310 (28.76%)         130 (32.02%)        180 (26.79%)       0.066       77 (30.31%)                                      233 (28.28%)                                  0.530
  CVA, *n* (%)                                 159 (14.75%)         61 (15.02%)         98 (14.58%)        0.843       30 (11.81%)                                      129 (15.66%)                                  0.131
  Hemiplegia, *n* (%)                          48 (4.45%)           19 (4.68%)          29 (4.32%)         0.779       11 (4.33%)                                       37 (4.49%)                                    0.914
  GI bleeding, *n* (%)                         296 (27.46%)         89 (21.92%)         207 (30.80%)       0.002       53 (20.87%)                                      243 (29.49%)                                  0.007
  Dementia, *n* (%)                            32 (2.97%)           7 (1.72%)           25 (3.72%)         0.061       6 (2.36%)                                        26 (3.16%)                                    0.515
  Cancer, *n* (%)                              228 (21.15%)         60 (14.78%)         168 (25.00%)       \<0.001     40 (15.75%)                                      188 (22.82%)                                  0.016
  Congestive heart failure, *n* (%)            553 (51.30%)         205 (50.49%)        348 (50.79%)       0.787       122 (48.41%)                                     431 (52.31%)                                  0.019
  Parameters at ICU admission                                                                                                                                                                                         
  BUN (mg/dL), median (range)                  56 (29.2--89)        63 (35--91)         50.5 (26.4--88)    0.001       51 (26--80.5)                                    57.7 (30--91.6)                               0.192
  sCr (mg/dL), median (range)                  3 (1.7--5.5)         4.1 (2.2--6.9)      2.6 (1.4--4.5)     \<0.001     3 (1.9--5.3)                                     3 (1.6--5.6)                                  0.984
  Lactate (mmol/L), median (range)             3.1 (1.7--7)         2.6 (1.3--5.2)      3.7 (2--8.6)       \<0.001     3 (1.6--6.1)                                     3.2 (1.7--7.3)                                0.030
  Etiology of AKI, *n* (%)                                                                                                                                                                                            
  Shock, *n* (%)                               616 (57.14%)         165 (40.64%)        451 (67.11%)       \<0.001     132 (51.97%)                                     484 (58.74%)                                  0.057
  Sepsis, *n* (%)                              770 (71.43%)         242 (59.61%)        528 (78.57%)       \<0.001     153 (60.24%)                                     617 (74.88%)                                  \<0.001
  Cardiorenal syndrome, *n* (%)                393 (36.46%)         170 (41.87%)        223 (33.18%)       0.010       93 (36.61%)                                      300 (36.41%)                                  0.952
  Nephrotoxic drugs, *n* (%)                   54 (5.01%)           27 (6.65%)          27 (4.02%)         0.055       22 (8.66%)                                       32 (3.88%)                                    0.002
  Rhabdomyolysis, *n* (%)                      81 (7.51%)           33 (8.13%)          48 (7.14%)         0.552       28 (11.02%)                                      53 (6.43%)                                    0.015
  Intravascular hemolysis, *n* (%)             34 (3.15%)           14 (3.45%)          20 (2.98%)         0.667       11 (4.33%)                                       23 (2.79%)                                    0.220
  Hepatorenal syndrome, *n* (%)                69 (6.40%)           4 (0.99%)           65 (9.67%)         \<0.001     4 (1.57%)                                        65 (7.89%)                                    \<0.001
  ATIN, *n* (%)                                9 (0.83%)            5 (1.23%)           4 (0.60%)          0.309       2 (0.79%)                                        7 (0.85%)                                     0.999
  Contrast exposure, *n* (%)                   75 (6.96%)           33 (8.13%)          42 (6.25%)         0.240       22 (8.66%)                                       53 (6.43%)                                    0.222
  Obstruction, *n* (%)                         12 (1.11%)           6 (1.48%)           6 (0.89%)          0.375       3 (1.18%)                                        9 (1.09%)                                     1.000
  Others, *n* (%)                              197 (18.27%)         103 (25.37%)        94 (13.99%)        \<0.001     61 (24.02%)                                      136 (16.50%)                                  0.007
  Parameters at RRT initiation                                                                                                                                                                                        
  Urine output (mL/24 h), median (range)       300 (90--822.5)      490 (160--1223)     204 (70--595)      \<0.001     520 (180--1305)                                  250 (75--670)                                 \<0.001
  AKI risk prediction score                    25 (19--33)          21 (16--28.3)       27.5 (22--35)      \<0.001     22 (17--29.3)                                    26 (21--34)                                   \<0.001
  Lactate (mmol/L), median (range)             3.2 (1.6--7.6)       2.3 (1.2--5.4)      3.9 (1.9--9.1)     \<0.001     2.8 (1.4--6.5)                                   3.3 (1.6--8.2)                                0.090
  SOFA score, median (range)                   12 (8--15)           9 (7--12)           13 (10--16)        \<0.001     10 (7--13)                                       12 (9--15)                                    \<0.001
  qSOFA, median (range)                        2 (1--2)             1 (1--2)            2 (1--2)           \<0.001     1 (1--2)                                         2 (1--2)                                      \<0.001
  qSOFA ≥ 2, *n* (%)                           582 (53.99%)         153 (37.66%)        429 (63.84%)       \<0.001     107 (42.13%)                                     475 (57.65%)                                  \<0.001
  APACHE II score, median (range)              24 (19--28)          20 (16--25)         25 (21--30)        \<0.001     21 (16--26)                                      24 (20--29)                                   \<0.001
  MODS score, median (range)                   11 (9--13)           10 (7--12)          11 (9--14)         \<0.001     10 (7.5--13)                                     11 (9--13)                                    0.008
  Sepsis 3 criteria                                                                                                                                                                                                   
  Sepsis, *n* (%)                              577 (53.53%)         152 (37.44%)        425 (63.24%)       \<0.001     106 (41.73%)                                     471 (57.16%)                                  \<0.001
  Septic shock, *n* (%)                        206 (19.11%)         34 (8.37%)          172 (25.60%)       \<0.001     31 (12.20%)                                      175 (21.24%)                                  0.001
  Site of infection, *n* (%)                                                                                                                                                                                          
  Respiratory                                  578 (53.62%)         188 (46.31%)        390 (58.04%)       \<0.001     1113 (44.49%)                                    465 (56.43%)                                  0.001
  GU                                           338 (31.35%)         134 (33.00%)        204 (30.36%)       0.364       83 (32.68%)                                      255 (30.95%)                                  0.603
  Bacteremia                                   237 (21.99%)         60 (14.78%)         177 (26.34%)       \<0.001     43 (16.93%)                                      194 (23.54%)                                  0.026
  Abdomen                                      114 (10.58%)         39 (9.61%)          75 (11.16%)        0.421       32 (12.60%)                                      82 (9.95%)                                    0.230
  Others                                       115 (10.67%)         37 (9.11%)          78 (11.61%)        0.199       25 (9.84%)                                       90 (10.92%)                                   0.626
  Indication for RRT                                                                                                                                                                                                  
  Azotemia, *n* (%)                            586 (54.36%)         220 (54.19%)        366 (54.46%)       0.929       113 (44.49%)                                     473 (57.40%)                                  \<0.001
  Fluid overload, *n* (%)                      604 (56.03%)         200 (49.26%)        404 (60.12%)       0.001       132 (51.97%)                                     472 (57.28%)                                  0.136
  Electrolyte imbalance, *n* (%)               417 (38.68%)         160 (39.41%)        257 (38.24%)       0.704       108 (42.52%)                                     309 (37.50%)                                  0.151
  Metabolic acidosis, *n* (%)                  535 (49.63%)         180 (44.33%)        355 (52.83%)       0.007       114 (44.88%)                                     421 (51.09%)                                  0.084
  Oliguria, *n* (%)                            694 (64.38%)         205 (50.49%)        489 (72.77%)       \<0.001     122 (48.03%)                                     572 (69.42%)                                  \<0.001
  Uremic encephalopathy, *n* (%)               78 (7.24%)           38 (9.36%)          40 (5.95%)         0.036       16 (6.30%)                                       62 (7.52%)                                    0.510
  First Dialysis modality, *n* (%)                                                                         \<0.001                                                                                                    0.239
  CVVH                                         371 (34.42%)         97 (23.89%)         274 (40.77%)                   79 (31.10%)                                      292 (35.44%)                                  
  IHD                                          644 (59.74%)         289 (71.18%)        355 (52.83%)                   163 (64.17%)                                     481 (58.37%)                                  
  SLEDD                                        63 (5.84%)           20 (4.93%)          43 (6.40%)                     12 (4.72%)                                       51 (6.19%)                                    
  Outcomes of interest                                                                                                                                                                                                
  90-day ICU free days                         7 (0--81)            81 (69--86)         0(0--1)            \<0.001     80 (68--86)                                      0 (0--54.5)                                   \<0.001
  90-day hospital free days                    0 (0--59.25)         63 (44.5--76)       0(0--0)            \<0.001     63 (42--76)                                      0 (0--2.5)                                    \<0.001
                                                                                                                                                                                                                      
                                                                                                                                                                                                                      
  Days of RRT in hospital, median (range)      10 (4--24)           11 (3--26)          9.5 (4--22.8)      0.461       5.5 (2--13.3)                                    12 (4--27.8)                                  \<0.001

Abbreviations: AKI, acute kidney injury; APACHE; acute physiology and chronic health evaluation; ATIN, acute tubule-interstitial nephritis; BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CVA, cerebrovascular accident; CVVH, continuous veno-venous hemofiltration; CPR, cardio-pulmonary resuscitation; eGFR, estimated glomerular filtration rate; GSC, Glasgow Coma Scale; GI, gastrointestinal; GU, genitourinary; IABP, intra-aortic balloon pump; ICU, intensive care unit; IHD, intermittent hemodialysis; IQR, interquartile range; MODS, multiple organ dysfunction; RRT, renal replacement therapy; sCr, serum creatinine; SLEDD, sustained low efficiency daily dialysis; SOFA, Sequential Organ Failure Assessment.
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###### 

Multivariable risk model for hospital mortality or composite outcome at discharge.

  Sepsis                             Non-Shock Sepsis vs Non-Sepsis   Septic Shock vs. Non-Sepsis                                       
  ---------------------------------- -------------------------------- ----------------------------- ------- -------------- ------------ -------
  Outcome of interests               Hazard Ratio                     95% CI                        *p*     Hazard Ratio   95% CI       *p*
  Hospital mortality                 1.12                             0.91--1.37                    0.276   1.48           1.17--1.88   0.001
  Hospital composite outcomes        0.97                             0.80--1.17                    0.732   1.24           1.08--1.47   0.047
  For 90-day mortality               1.23                             1.02--1.47                    0.027   1.39           1.11--1.75   0.004
  For 90-day composite outcome       1.26                             1.03--1.53                    0.022   1.45           1.15--1.83   0.002
  For 90-day weaning from dialysis   0.96                             0.76--1.22                    0.760   0.65           0.45--0.95   0.026

*p*; paired comparison between the groups. All relevant covariates included in the multi-variable analysis, including age, sex, baseline comorbidities, indication for dialysis, etiology of AKI, kidney profile and SOFA score at dialysis initiation, dialysis modality, and some of their interactions. Abbreviations: AKI, acute kidney injury; CI, confidence interval.
